INMB · Inmune Bio, Inc.
$2.17
+0.09 (+4.33%)
At close · Aug 14
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Given the Company's projected operating requirements and its existing cash and cash equivalents, the Company is projecting insufficient liquidity to sustain its operations through one year following the date that the financial statements are issued. These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. Because management's plans have not yet been finalized and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$60.23M
Shares
27.75M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.17
Open$2.09
Day$2.04–2.20
52W close$1.12–2.53
Avg vol 30d583K
Short int2.2M · 7.9% float · 6.6d
Short vol32%
Last earningsMar 31, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+40%
above
Price vs 50-day avg
+28%
above
RSI (14)
67
neutral
MACD trend
Positive
52-week position
74%
mid-range
Momentum
relative strength
1-month return
+14%
trailing
6-month return
+72%
trailing
YTD return
+39%
this year
Relative strength
+58%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +23 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.94% of float · ▼ -7.6% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
82 holders — mid 3-yr range
Squeeze score
78
high risk · 0–100
Fundamentals
Revenue growth
+257%
Y/Y
EPS growth
+12%
Y/Y
Free cash flow
$-23.6M
Balance sheet
$5.1M
net cash
Quant / Vol
risk profile
Volatility
72%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+40%
Bullish
Price vs 50-day avg
+28%
Bullish
RSI (14)
67
Neutral
MACD trend
Positive
Bullish
52-week position
74%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +23 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.94% of float · ▼ -7.6% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
82 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 74%
Range high $3
vs 200-day avg +40%
vs 50-day avg +28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INMB
this stock
Inmune Bio, Inc.
|
$60.23M | +39.1% | +257.1% | — | 7.9% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INMB | +4.1% | +14.2% | +72.2% | +24.0% | +39.1% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +3.7% | +9.8% | +58.5% | +20.1% | +25.3% |
Key facts
CIK
1711754
CUSIP
45782T105
13F (30d)
78 filings
78 filers
Visit website
Investor relations